Holen Sie sich die Stockscreener-App
1.21
14.18%
-0.20
Handel nachbörslich:
1.21
Schlusskurs vom Vortag:
$1.41
Offen:
$1.09
24-Stunden-Volumen:
28,741
Relative Volume:
0.25
Marktkapitalisierung:
$3.24M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.01M
KGV:
-0.1833
EPS:
-6.6
Netto-Cashflow:
$-18.31M
1W Leistung:
-67.21%
1M Leistung:
-67.39%
6M Leistung:
-80.85%
1J Leistung:
-85.92%
1-Tages-Spanne:
$1.00
$1.36
1-Wochen-Bereich:
$1.00
$4.04
52-Wochen-Spanne:
$1.00
$13.02
Vaccinex Inc Stock (VCNX) Company Profile
Firmenname
Vaccinex Inc
Sektor
Branche
Telefon
585-271-2700
Adresse
1895 MOUNT HOPE AVE, ROCHESTER, NY
Vergleichen Sie VCNX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VCNX
Vaccinex Inc
|
1.21 | 3.24M | 0 | -22.01M | -18.31M | -85.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vaccinex Inc Stock (VCNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-09-23 | Herabstufung | BTIG Research | Buy → Neutral |
| 2018-09-04 | Eingeleitet | Ladenburg Thalmann | Buy |
Vaccinex Inc Aktie (VCNX) Neueste Nachrichten
Vaccinex Stock to Be Delisted From Nasdaq - Marketscreener.com
Vaccinex (OTC:VCNX) Stock Quotes, Forecast and News Summary - Benzinga
Vaccinex Faces Delisting from Nasdaq, Details Plans for OTC Quotation - Defense World
Vaccinex to be delisted from Nasdaq over equity shortfall By Investing.com - Investing.com South Africa
Vaccinex to be delisted from Nasdaq over equity shortfall - Investing.com India
Vaccinex Shares Tumble 63% On Nasdaq Delisting - MarketWatch
Vaccinex Faces Nasdaq Delisting Amid Financial Struggles; Shares Drop 62% - Yahoo Finance
Vaccinex stock plunges to 52-week low at $1.36 amid market challenges - Investing.com
Vaccinex Announces Receipt of Delisting Notification from Nasdaq - The Manila Times
Vaccinex Faces Nasdaq Delisting After Failing Minimum Equity Requirements, Moves to OTC Markets - StockTitan
Vaccinex (NASDAQ:VCNX) Trading 11.1% Higher – Time to Buy? - Defense World
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Vaccinex Reports Promising Alzheimer's Drug Data, Raises $8.35M Amid Financial Challenges | VCNX Stock News - StockTitan
Vaccinex secures $2.15 million in private placement - Investing.com
Vaccinex Inc (VCNX) Quarterly 10-Q Report - Quartzy
Vaccinex secures $2.15 million in private placement By Investing.com - Investing.com UK
ARMISTICE CAPITAL, LLC Acquires Shares in Vaccinex Inc - GuruFocus.com
Vaccinex, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Latest Company News - Investing.com
Vaccinex inks multiple antibody discovery deals using ActivMAb By Investing.com - Investing.com Canada
Vaccinex inks multiple antibody discovery deals using ActivMAb - Investing.com India
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC - GlobeNewswire
Vaccinex Lands Major Pharma Deals: Amgen, Merck Partner on Breakthrough Antibody Tech | VCNX Stock News - StockTitan
Vaccinex Reports Improved Immunity Correlating with - GlobeNewswire
VCNXVaccinex, Inc. Latest Stock News & Market Updates - StockTitan
Vaccinex's Pepinemab Breakthrough: New Data Shows Enhanced Cancer Immunotherapy Success | VCNX Stock News - StockTitan
Vaccinex reports progress in Alzheimer's treatment study By Investing.com - Investing.com Canada
Vaccinex reports progress in Alzheimer's treatment study - Investing.com India
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 - GlobeNewswire
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, Spain - Nasdaq
Vaccinex stock tanks 40% despite positive Alzheimer’s study update - MSN
Vaccinex Stock Spikes On 'Promising' Data On Alzheimer’s Drug Study: Retail Sentiment Brightens - Barchart
Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024 - GlobeNewswire
Micron Technology (MU-Q) QuotePress Release - The Globe and Mail
Orange Juice (OJX25) Quote - The Globe and Mail
Antibody Library Technology Market Report to 2032 -AnaptysBio Inc, MorphoSys AG, XOMA Corporation, Abzena Plc, AvantGen – IndiaPolitics.com - IndiaPolitics.com
Vaccinex faces potential Nasdaq delisting over equity shortfall - Investing.com India
BTIG Research’s latest rating for VCNX stock - Knox Daily
Vaccinex faces potential Nasdaq delisting over equity shortfall By Investing.com - Investing.com Canada
Company’s Banking Shares: Up -90.42% from 52-Week Low, But Can the Momentum Hold? - The InvestChronicle
Post-Trade Analysis: Vaccinex Inc (VCNX) Slides -27.92, Closing at 1.73 - The Dwinnex
Vaccinex stock hits 52-week low at $2.98 amid market challenges - Investing.com
Vaccinex stock hits 52-week low at $4.17 amid sharp annual decline - Investing.com Canada
VSME’s price-to-free cash flow ratio: What it means for investors - US Post News
Short Interest in Victory Square Technologies Inc. (OTCMKTS:VSQTF) Declines By 79.4% - Defense World
Viemed Healthcare, Inc. (NASDAQ:VMD) Shares Purchased by Victory Capital Management Inc. - Defense World
WUXI BIO Buys back ~3.32M Shrs for ~$42.55M Ytd - AASTOCKS.com
Finanzdaten der Vaccinex Inc-Aktie (VCNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Vaccinex Inc-Aktie (VCNX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| FRIEDBERG ALBERT | Director |
Sep 18 '24 |
Option Exercise |
5.64 |
240,009 |
1,352,691 |
1,020,633 |
| FRIEDBERG ALBERT | Director |
Aug 09 '24 |
Buy |
4.51 |
100 |
451 |
780,624 |
| FRIEDBERG ALBERT | Director |
Aug 05 '24 |
Buy |
4.60 |
3,653 |
16,804 |
777,771 |
| FRIEDBERG ALBERT | Director |
Aug 06 '24 |
Buy |
4.92 |
2,753 |
13,545 |
780,524 |
| FRIEDBERG ALBERT | Director |
Aug 01 '24 |
Buy |
4.72 |
11,703 |
55,238 |
774,118 |
| FRIEDBERG ALBERT | Director |
Jul 31 '24 |
Buy |
6.15 |
200,000 |
1,230,280 |
762,415 |
| FRIEDBERG ALBERT | Director |
May 29 '24 |
Buy |
4.95 |
957 |
4,737 |
561,554 |
| FRIEDBERG ALBERT | Director |
May 30 '24 |
Buy |
5.20 |
861 |
4,473 |
562,415 |
| FRIEDBERG ALBERT | Director |
Apr 19 '24 |
Buy |
4.73 |
282 |
1,334 |
560,597 |
| Van Strydonck, Gerald E. | Director |
Dec 26 '23 |
Sale |
0.72 |
3,149 |
2,267 |
0 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):